[Therapy of heart failure with combined furosemide retard/triamterene].
20 patients with an average age of 73.3 years suffering from left cardiac insufficiency in stage II to III of the NYHA, who could not be recompensated alone by means of digitalisation, received additionally the diuretic combination furosemide-retard (30 mg)/triamterene (50 mg) for 2 to 3 weeks. Subjective side effects were not observed. The laboratory parameters did not show any substantial changes. A short increase of uric acid and serum creatinine in the older patients returned to normal spontaneously. A decreased potassium level returned to normal; a hyperkaliemia was not observed. The repeated administration of the combination did not lead to any accumulation; only a balanced concentration at a low level appeared. The urine elimination, the decrease in body weight, the regression of the lung congestion and the size of the heart were statistically significant.
D000368:Aged; D002784:Cholesterol / Q000097:blood; D003404:Creatinine / Q000097:blood; D003692:Delayed-Action Preparations; D004338:Drug Combinations; D005260:Female; D005665:Furosemide / Q000627:therapeutic use*; D006333:Heart Failure / Q000097:blood / Q000188:drug therapy*; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D008297:Male; D011188:Potassium / Q000097:blood; D014223:Triamterene / Q000627:therapeutic use*; D014527:Uric Acid / Q000097:blood
D003692:Delayed-Action Preparations; D004338:Drug Combinations; D014527:Uric Acid; D005665:Furosemide; D002784:Cholesterol; D003404:Creatinine; D011188:Potassium; D014223:Triamterene
Therapie der Herzinsuffizienz mit der Kombination Furosemid retard/Triamteren.